Nutriband Inc. (NTRBW)
- Previous Close
1.1800 - Open
1.2500 - Bid --
- Ask --
- Day's Range
1.2500 - 1.2500 - 52 Week Range
0.4600 - 5.2500 - Volume
757 - Avg. Volume
6,280 - Market Cap (intraday)
-- - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5050 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
www.nutriband.comRecent News: NTRBW
View More
Performance Overview: NTRBW
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTRBW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTRBW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.79%
Return on Equity (ttm)
-162.94%
Revenue (ttm)
2.14M
Net Income Avi to Common (ttm)
-10.48M
Diluted EPS (ttm)
-0.5050
Balance Sheet and Cash Flow
Total Cash (mrq)
4.31M
Total Debt/Equity (mrq)
2.90%
Levered Free Cash Flow (ttm)
-3.94M